Pharmaceutical companies, pressured by buyers to lower drug prices, find their high profit margins threatened.
Selling software as a service instead of a product has been a boon for enterprise software companies. But will their growth translate to high profits?
A Prescription for Growth? Why Pharma Companies Are Testing New Tactics to Refill Their Drug Pipelines
Many pharmaceutical companies are shifting away from large acquisitions, instead opting to buy smaller firms with riskier, earlier-stage drug candidates. Others are experimenting with new strategies altogether.
To regain market share lost to nimble competitors, established footwear and apparel brands are taking steps to accelerate design, production, and sales.
As top-selling biologics begin to lose patent protection, some drug makers are investing heavily to meet anticipated demand for biosimilars. Yet the high cost and complexity of these new drugs pose a risk to expected profits.
In-store apps and “digitized” brick-and-mortar stores point to a future where online and offline shopping is highly integrated.
Climate change and other global trends could lead to more encounters with pests—and rising demand for pest control services.
Fixed-base operators that run a network of locations are likely to achieve higher-than-average earnings growth in the fragmented FBO industry.
Greater precision and speed, combined with lower energy requirements, give lasers a meaningful advantage over other manufacturing tools—and a long growth trajectory for laser equipment companies.
Unlike Christmas, Diwali, or Chinese New Year, Ramadan shifts about 11 days earlier each year and is not confined to a single season—or financial quarter.
Peer-to-peer lending platforms have flourished in a period of steady economic growth, but their popularity with lenders may decline during the next downturn.
If global demand for food is rising, why did producers of a key fertilizer falter?